{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T16:40:58Z","timestamp":1745772058646},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1053\/j.seminoncol.2007.10.005","type":"journal-article","created":{"date-parts":[[2008,4,14]],"date-time":"2008-04-14T23:11:54Z","timestamp":1208214714000},"page":"S4-S10","source":"Crossref","is-referenced-by-count":20,"special_numbering":"S4","title":["Reducing the Risk of Cancer Treatment-Associated Bone Loss in Patients With Breast Cancer"],"prefix":"10.1053","volume":"34","author":[{"given":"Peyman","family":"Hadji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel","family":"Bundred","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2007.10.005_bib1","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(02)08761-5","article-title":"Diagnosis of osteoporosis and assessment of fracture risk","volume":"359","author":"Kanis","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib2","unstructured":"National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Breast Cancer. v.2. 2007. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/breast.pdf. Accessed November 6, 2007"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib3","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","article-title":"Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group","volume":"25","author":"Gnant","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib4","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminoncol.2007.10.005_bib5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1359-6349(06)80035-2","article-title":"Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZOFAST study)","volume":"4","author":"Bundred","year":"2006","journal-title":"Eur J Cancer Suppl"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib6","series-title":"The E-ZO-FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole (Let) [poster]","author":"Schenk","year":"2007"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib7","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1172\/JCI11468","article-title":"The mechanisms of estrogen regulation of bone resorption","volume":"106","author":"Riggs","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib8","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1172\/JCI28550","article-title":"Estrogen deficiency and bone loss: An inflammatory tale","volume":"116","author":"Weitzmann","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJM199809103391104","article-title":"Endogenous hormones and the risk of hip and vertebral fractures among older women","volume":"339","author":"Cummings","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib10","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1634\/theoncologist.11-10-1121","article-title":"Bone loss and fracture risk associated with cancer therapy","volume":"11","author":"Guise","year":"2006","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib11","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bjc.6690188","article-title":"A high incidence of vertebral fracture in women with breast cancer","volume":"79","author":"Kanis","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib12","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archinte.165.5.552","article-title":"Fracture risk among breast cancer survivors","volume":"165","author":"Chen","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib14","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Thurlimann","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib15","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","article-title":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years\u2019 adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz","year":"2005","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib17","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2006.24.18_suppl.511","article-title":"Effect of anastrozole on bone mineral density: 5-year results from the \u2018Arimidex\u2019, Tamoxifen, Alone or in Combination (ATAC) trial","volume":"24","author":"Coleman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","article-title":"Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study","volume":"8","author":"Coleman","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib19","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib20","first-page":"35","article-title":"Aromatase inhibitor-associated bone loss in breast cancer","volume":"1","author":"Hadji","year":"2007","journal-title":"Eur Oncol Dis"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib21","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98","volume":"25","author":"Coates","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib22","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib24","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","article-title":"Bone mineral density thresholds for pharmacological intervention to prevent fractures","volume":"164","author":"Siris","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib25","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJM199503233321202","article-title":"Risk factors for hip fracture in white women","volume":"332","author":"Cummings","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib26","series-title":"Do we need DXA assessment of breast cancer patients following 5 years tamoxifen therapy prior to commencing letrozole? [poster]","author":"Whannel","year":"2006"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib27","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/bjc.1997.105","article-title":"Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens","volume":"75","author":"Saarto","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib28","doi-asserted-by":"crossref","first-page":"46s","DOI":"10.1200\/jco.2006.24.18_suppl.676","article-title":"10-year follow-up of the efficacy of clodronate on bone mineral density (BMD) in early stage breast cancer","volume":"24","author":"Saarto","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1023\/B:BREA.0000041624.00665.4e","article-title":"Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure","volume":"87","author":"Vehmanen","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib30","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","article-title":"Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study","volume":"15","author":"Delmas","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01623453","article-title":"Who are candidates for prevention and treatment for osteoporosis?","volume":"7","year":"1997","journal-title":"Osteoporos Int"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib32","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","article-title":"Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)","volume":"21","author":"Eastell","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib33","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s001980170006","article-title":"Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds","volume":"12","author":"Kanis","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib34","doi-asserted-by":"crossref","first-page":"16s","DOI":"10.1200\/jco.2007.25.18_suppl.553","article-title":"Effect of monthly oral ibandronate on anastrozole-induced bone loss during adjuvant treatment for breast cancer: One year results from the ARIBON study","volume":"25","author":"Lester","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.10.005_bib35","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejon.2006.04.025","article-title":"Gastrointestinal side effects can reduce compliance with oral bisphosphonate therapy in cancer patients","volume":"10","author":"Heatley","year":"2006","journal-title":"Eur J Oncol Nurs"},{"issue":"1","key":"10.1053\/j.seminoncol.2007.10.005_bib36","first-page":"S233","article-title":"Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET)","volume":"100","author":"Brufsky","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1053\/j.seminoncol.2007.10.005_bib37","first-page":"S25","article-title":"An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET)","volume":"100","author":"Brufsky","year":"2006","journal-title":"Breast Cancer Res Treat"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775407002072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775407002072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T05:08:15Z","timestamp":1588568895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775407002072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":36,"alternative-id":["S0093775407002072"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2007.10.005","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}